tradingkey.logo

AstraZeneca's breast cancer drug may be part of Chinese import investigation, CEO says

ReutersFeb 6, 2025 10:12 AM

- AstraZeneca AZN.L and Daiichi Sankyo's 4568.T breast cancer treatment Enhertu, might be part of a Chinese investigation into the import of AstraZeneca's cancer medications, Chief Executive Pascal Soriot told media on Thursday.

Earlier in the day, the company said it could face a fine of up to $4.5 million in China for possibly unpaid import taxes on two other cancer drugs, Imfinzi and Imjudo. The company first reported this investigation in November.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI